Stephen Locarnini Selected Research

Stephen Locarnini Research Topics

Disease

42	Chronic Hepatitis B 01/2022 - 09/2002
37	Hepatitis B 01/2022 - 02/2002
30	Infections 01/2022 - 02/2002
9	Coinfection 01/2020 - 09/2008
7	Hepatocellular Carcinoma (Hepatoma) 01/2018 - 01/2009
7	Liver Diseases (Liver Disease) 01/2018 - 12/2002
6	Persistent Infection 01/2018 - 06/2004
6	Hepatitis 11/2015 - 02/2002
6	Fibrosis (Cirrhosis) 04/2015 - 09/2008
5	Disease Progression 01/2017 - 02/2002
3	HIV Infections (HIV Infection) 05/2013 - 05/2004
3	Liver Failure 10/2004 - 02/2002
2	Viremia 01/2016 - 05/2013
2	Hepatitis C 01/2015 - 04/2002
2	Virus Diseases (Viral Diseases) 06/2012 - 01/2008
2	Liver Cirrhosis (Hepatic Cirrhosis) 09/2010 - 09/2008
1	Chronic Kidney Failure (Chronic Renal Failure) 04/2021
1	Liver Neoplasms (Liver Cancer) 01/2018
1	Superinfection 01/2013
1	Acquired Immunodeficiency Syndrome (AIDS) 01/2011
1	Inflammation (Inflammations) 09/2010
1	Necrosis 01/2009
1	Hepatoblastoma 01/2009
1	Immune Reconstitution Inflammatory Syndrome 01/2007
1	Iron Overload 04/2002
1	Chronic Hepatitis C 04/2002
1	beta-Thalassemia (Cooley's Anemia) 04/2002
1	Massive Hepatic Necrosis 01/2002

Drug/Important Bio-Agent (IBA)

26	Antiviral Agents (Antivirals)IBA 01/2020 - 02/2002
20	Hepatitis B e AntigensIBA 01/2022 - 06/2005
17	Hepatitis B Surface Antigens (HBsAg)FDA Link 01/2022 - 09/2002
15	DNA (Deoxyribonucleic Acid)IBA 04/2021 - 01/2004
11	Pharmaceutical PreparationsIBA 12/2015 - 02/2002
11	Lamivudine (Epivir)FDA Link 03/2012 - 01/2002
8	VaccinesIBA 01/2018 - 12/2004
7	Proteins (Proteins, Gene)FDA Link 11/2013 - 05/2003
6	Tenofovir (Viread)FDA Link 11/2017 - 01/2005
5	Biomarkers (Surrogate Marker)IBA 11/2019 - 11/2011
4	RNA (Ribonucleic Acid)IBA 01/2022 - 09/2008
4	NucleotidesIBA 01/2020 - 07/2003
4	Surface Antigens (Surface Antigen)IBA 06/2012 - 08/2003
4	NucleosidesIBA 01/2010 - 02/2002
4	adefovir dipivoxil (Hepsera)FDA Link 05/2008 - 07/2003
3	AntigensIBA 01/2022 - 11/2007
3	Nucleic AcidsIBA 01/2022 - 11/2007
3	Alanine Transaminase (SGPT)IBA 04/2015 - 10/2004
2	entecavir FDA Link 01/2022 - 12/2004
2	EpitopesIBA 01/2022 - 11/2019
2	lipoarabinomannan (LAM)IBA 01/2017 - 08/2009
2	TolerogenIBA 03/2011 - 01/2010
2	RacivirIBA 08/2009 - 05/2008
2	Hepatitis B virus P proteinIBA 05/2009 - 09/2008
2	CytokinesIBA 01/2009 - 05/2004
2	Toll-Like Receptor 2IBA 01/2009 - 08/2006
2	InterferonsIBA 07/2007 - 04/2002
1	ARC-520IBA 01/2022
1	Viral RNAIBA 01/2020
1	AntibodiesIBA 01/2020
1	Immunologic Factors (Immunomodulators)IBA 06/2017
1	Membrane Proteins (Integral Membrane Proteins)IBA 01/2017
1	Terminator Codon (Termination Codon)IBA 01/2017
1	Peptide Hydrolases (Proteases)FDA Link 01/2015
1	N- (3- amino- 1- (cyclobutylmethyl)- 2,3- dioxopropyl)- 3- (2- ((((1,1- dimethylethyl)amino)carbonyl)amino)- 3,3- dimethyl- 1- oxobutyl)- 6,6- dimethyl- 3- azabicyclo(3.1.0)hexan- 2- carboxamideIBA 01/2015
1	Viral ProteinsIBA 09/2012
1	Interleukin-8 (Interleukin 8)IBA 01/2009
1	NF-kappa B (NF-kB)IBA 01/2009
1	Interleukin-1 Receptors (Interleukin 1 Receptor)IBA 01/2009
1	Toll-Like Receptors (Toll-Like Receptor)IBA 01/2009
1	pgRNAIBA 09/2008
1	Emtricitabine (Emtriva)FDA Link 05/2008
1	N-acetyltalosaminuronic acid (NAT)IBA 11/2007
1	nasIBA 07/2007
1	Neutralizing AntibodiesIBA 01/2007
1	Adenosine (Adenocard)FDA LinkGeneric 01/2005
1	Circular DNAIBA 06/2004
1	Immunoglobulins (Immunoglobulin)IBA 08/2003
1	Famciclovir (Famvir)FDA LinkGeneric 05/2003
1	Interferon-alpha (Interferon Alfa)IBA 04/2002
1	IronIBA 04/2002
1	BilirubinIBA 02/2002
1	hepatitis B hyperimmune globulinIBA 02/2002
1	Transaminases (Aminotransferases)IBA 02/2002

Therapy/Procedure

36	Therapeutics 01/2020 - 02/2002
6	Highly Active Antiretroviral Therapy (HAART) 01/2016 - 05/2004
5	Drug Therapy (Chemotherapy) 06/2012 - 12/2002
3	Liver Transplantation 06/2012 - 02/2002
2	Cell Transplantation 02/2005 - 09/2002
2	Transplantation 02/2005 - 09/2002
2	Combination Drug Therapy (Combination Chemotherapy) 01/2004 - 09/2002
1	Salvage Therapy 01/2017
1	Immunomodulation 10/2011
1	Bone Marrow Transplantation (Transplantation, Bone Marrow) 02/2005